SCHEMBL9944285

SCHEMBL9944285

COc1c(Cl)cc(C(=O)Nc2ccc(C=O)cc2)cc1OC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.57
TAS1R1 Q7RTX1 2/20 0.57
TAS1R2 Q8TE23 2/20 0.57
ABCB1 P08183 1/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 1/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 5/20 0.47
LMNA P02545 3/20 0.47
GAA P10253 2/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
MAPK1 P28482 2/20 0.46
MCL1 Q07820 2/20 0.46
GFER P55789 1/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PLAU P00749 1/20 0.43
RORC P51449 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944327 0.92 ABCB1 (0.56) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944313 0.91 TAS1R3 (0.54) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944346 0.89 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944310 0.88 MEN1 (0.50) TAS1R3TAS1R1TAS1R2ALDH1A1HPGD
SCHEMBL9944292 0.87 TOP1 (0.49) ABCB1ALDH1A1MEN1KMT2AMAPT
SCHEMBL9944339 0.86 MAPT (0.50) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944212 0.86 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL1458322 0.86 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944353 0.85 TAS1R3 (0.50) TAS1R3TAS1R1TAS1R2ABCB1ALDH1A1
SCHEMBL9944330 0.84 GAA (0.51) TAS1R3TAS1R1TAS1R2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.